JP2024525993A - Ｋｒａｓ ｇ１２ｄ阻害剤およびその使用 - Google Patents
Ｋｒａｓ ｇ１２ｄ阻害剤およびその使用 Download PDFInfo
- Publication number
- JP2024525993A JP2024525993A JP2024527720A JP2024527720A JP2024525993A JP 2024525993 A JP2024525993 A JP 2024525993A JP 2024527720 A JP2024527720 A JP 2024527720A JP 2024527720 A JP2024527720 A JP 2024527720A JP 2024525993 A JP2024525993 A JP 2024525993A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharma
- acceptable salt
- compound
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021108280 | 2021-07-23 | ||
| CNPCT/CN2021/108280 | 2021-07-23 | ||
| CN2021143176 | 2021-12-30 | ||
| CNPCT/CN2021/143176 | 2021-12-30 | ||
| PCT/CN2022/106447 WO2023001141A1 (en) | 2021-07-23 | 2022-07-19 | Kras g12d inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525993A true JP2024525993A (ja) | 2024-07-12 |
| JP2024525993A5 JP2024525993A5 (cg-RX-API-DMAC10.html) | 2025-07-29 |
Family
ID=84979988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527720A Pending JP2024525993A (ja) | 2021-07-23 | 2022-07-19 | Ｋｒａｓ ｇ１２ｄ阻害剤およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240376123A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4373827A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024525993A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240087636A (cg-RX-API-DMAC10.html) |
| CN (1) | CN117242079A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022314009A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3226720A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023001141A1 (cg-RX-API-DMAC10.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024510022A (ja) * | 2021-03-17 | 2024-03-05 | ▲勁▼方医▲薬▼科技（上海）有限公司 | ピリミジン縮合環系化合物、その製造方法、及び使用 |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| CN116867792A (zh) * | 2021-02-09 | 2023-10-10 | 基因泰克公司 | 四环氧氮杂䓬化合物及其用途 |
| MX2023015533A (es) * | 2021-06-21 | 2024-01-23 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| JP2025504041A (ja) * | 2022-01-30 | 2025-02-06 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | キノリン系化合物及びその使用 |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| EP4511127A1 (en) * | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2023265688A1 (en) | 2022-05-06 | 2024-10-17 | PAQ Therapeutics Inc. | Kras g12d proteolysis targeting chimeras |
| CN119365467A (zh) * | 2022-05-19 | 2025-01-24 | 基因泰克公司 | 氮杂-四环氧氮杂䓬化合物及其用途 |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| TW202409051A (zh) * | 2022-07-27 | 2024-03-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠環類化合物、其製備方法及其在醫藥上的應用 |
| KR20250037564A (ko) * | 2022-07-29 | 2025-03-17 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Kras g12d 억제제를 포함하는 약학적 조성물 |
| AU2023320565A1 (en) | 2022-08-05 | 2025-01-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2024032704A1 (en) * | 2022-08-11 | 2024-02-15 | Beigene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2024041573A1 (en) * | 2022-08-25 | 2024-02-29 | Zai Lab (Shanghai) Co., Ltd. | Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof |
| WO2024051721A1 (en) * | 2022-09-07 | 2024-03-14 | Nikang Therapeutics, Inc. | Tetracyclic derivatives as kras inhibitors |
| TW202426459A (zh) * | 2022-09-23 | 2024-07-01 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| TW202440594A (zh) * | 2022-12-07 | 2024-10-16 | 大陸商北京加科思新藥研發有限公司 | 稠環化合物及其用途 |
| TW202430184A (zh) * | 2022-12-20 | 2024-08-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | Kras g12d抑制劑的結晶形式及製備方法 |
| CN122187841A (zh) * | 2023-01-18 | 2026-06-12 | 苏州赞荣医药科技有限公司 | Kras g12d抑制剂和其用途 |
| WO2024234360A1 (en) * | 2023-05-18 | 2024-11-21 | Nikang Therapeutics , Inc. | Tetracyclic derivatives as kras inhibitors |
| WO2024159471A1 (en) * | 2023-02-02 | 2024-08-08 | Nikang Therapeutics , Inc. | Tetracyclic derivatives as kras inhibitors |
| WO2024159470A1 (en) * | 2023-02-02 | 2024-08-08 | Nikang Therapeutics , Inc. | Tetracyclic derivatives as kras inhibitors |
| WO2024160225A1 (en) * | 2023-02-02 | 2024-08-08 | Nikang Therapeutics, Inc. | Tetracyclic derivatives as kras inhibitors |
| EP4680609A1 (en) | 2023-03-15 | 2026-01-21 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| WO2024197503A1 (en) * | 2023-03-27 | 2024-10-03 | Nikang Therapeutics , Inc. | Tricyclic derivatives as kras inhibitors |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| WO2024208305A1 (zh) * | 2023-04-07 | 2024-10-10 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| WO2024213979A1 (en) * | 2023-04-10 | 2024-10-17 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2024215754A1 (en) * | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| EP4695261A1 (en) | 2023-04-14 | 2026-02-18 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| WO2024218686A1 (en) * | 2023-04-20 | 2024-10-24 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| WO2024230707A1 (zh) * | 2023-05-07 | 2024-11-14 | 上海医药集团股份有限公司 | 一种喹唑啉类化合物及其应用 |
| EP4716531A2 (en) * | 2023-05-22 | 2026-04-01 | Board of Regents, The University of Texas System | Heterocyclic compounds as nras inhibitors |
| WO2025016899A1 (en) | 2023-07-19 | 2025-01-23 | Bayer Aktiengesellschaft | Spirocyclic compounds for the treatment of cancer |
| WO2025026903A1 (en) | 2023-07-31 | 2025-02-06 | Bayer Aktiengesellschaft | Imidazo pyrimidine compounds for the treatment of cancer |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| EP4766713A2 (en) * | 2023-08-25 | 2026-07-01 | Ensem Therapeutics, Inc. | TETRACYCLIC DERIVATIVES, COMPOSITIONS AND ASSOCIATED PROCESSES |
| WO2025045141A1 (en) * | 2023-08-31 | 2025-03-06 | Suzhou Zanrong Pharma Limited | Kras inhibitors and uses thereof |
| EP4774280A1 (en) * | 2023-09-08 | 2026-07-15 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) * | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025059040A1 (en) * | 2023-09-11 | 2025-03-20 | Newave Pharmaceutical Inc. | Mutant kras modulators and uses thereof |
| KR20260087586A (ko) | 2023-10-03 | 2026-06-11 | 피에이큐 테라퓨틱스 인코포레이티드 | Kras 단백질분해 표적화 키메라 |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| KR20260110993A (ko) | 2023-10-09 | 2026-07-14 | 인사이트 코포레이션 | Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| KR20260096846A (ko) | 2023-10-20 | 2026-06-24 | 머크 샤프 앤드 돔 엘엘씨 | Kras 단백질의 소분자 억제제 |
| TW202540122A (zh) * | 2023-11-22 | 2025-10-16 | 美商建南德克公司 | Ｋｒａｓ－ｇ１２ｄ之氮雜－四環氧氮呯抑制劑的多晶型物及合成方法 |
| WO2025111582A1 (en) * | 2023-11-22 | 2025-05-30 | Genentech, Inc. | Aza-tetracyclic oxazepine inhibitors of kras-g12d |
| WO2025123318A1 (en) * | 2023-12-15 | 2025-06-19 | Shanghai Blueray Biopharma Co., Ltd. | TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS |
| WO2025146194A1 (en) * | 2024-01-05 | 2025-07-10 | Jacobio Pharmaceuticals Co., Ltd. | Fused tetracyclic compounds and use thereof |
| AU2025209726A1 (en) * | 2024-01-17 | 2026-07-09 | Suzhou Zanrong Pharma Limited | Kras inhibitors and uses thereof |
| CN119684315B (zh) * | 2024-01-26 | 2026-05-12 | 苏州盛迪亚生物医药有限公司 | 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025194134A1 (en) * | 2024-03-15 | 2025-09-18 | Genentech, Inc. | Linearly substituted oxazepin-5-one kras-g12d inhibitors |
| WO2025217319A1 (en) * | 2024-04-09 | 2025-10-16 | Kestrel Therapeutics Inc. | Ras inhibitors and methods of use thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| TW202615038A (zh) | 2024-08-07 | 2026-04-16 | 美商太斯萊特醫藥美國有限責任公司 | 包含拓樸異構酶有效載荷之靶向ｋｒａｓ之共價誘導之藥物結合物 |
| WO2026039659A1 (en) * | 2024-08-14 | 2026-02-19 | Board Of Regents, The University Of Texas System | Heterocyclic compounds as ras inhibitors |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026072560A1 (en) * | 2024-09-30 | 2026-04-02 | Ensem Therapeutics, Inc. | Tetracyclic derivatives, compositions and methods thereof |
| WO2026080226A1 (en) * | 2024-10-08 | 2026-04-16 | Ensem Therapeutics, Inc. | Tricyclic derivatives, compositions and methods thereof |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090333A1 (en) | 2024-10-23 | 2026-04-30 | Incyte Corporation | Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer |
| US20260137674A1 (en) | 2024-10-23 | 2026-05-21 | Incyte Corporation | Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112187A1 (en) * | 2024-11-20 | 2026-05-28 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026158694A1 (zh) * | 2025-01-27 | 2026-07-30 | 江苏亚虹医药科技股份有限公司 | Cdk抑制剂及其制备方法和用途 |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019215203A1 (en) * | 2018-05-08 | 2019-11-14 | Astrazeneca Ab | Tetracyclic heteroaryl compounds |
| JP2020519589A (ja) * | 2017-05-11 | 2020-07-02 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | Ｇ１２ｃ変異型ｒａｓタンパク質を阻害するヘテロアリール化合物 |
| JP2024500105A (ja) * | 2020-12-15 | 2024-01-04 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | ポリヌクレオチドの改善されたインビトロアセンブリーのための組成物及び方法 |
| JP2024510022A (ja) * | 2021-03-17 | 2024-03-05 | ▲勁▼方医▲薬▼科技（上海）有限公司 | ピリミジン縮合環系化合物、その製造方法、及び使用 |
| JP2024513866A (ja) * | 2021-04-04 | 2024-03-27 | 華為技術有限公司 | データ伝送方法及び装置 |
| JP2024522766A (ja) * | 2021-06-21 | 2024-06-21 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合四環系化合物、その調製方法及びその医薬的応用 |
| JP2024545001A (ja) * | 2021-11-16 | 2024-12-05 | ワッカー ケミー アクチエンゲゼルシャフト | 亜ハロゲン化ケイ素含有複合粒子 |
| JP2025513258A (ja) * | 2022-04-21 | 2025-04-24 | ギリアード サイエンシーズ， インコーポレイテッド | Ｋｒａ ｇ１２ｄ調節化合物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10597405B2 (en) * | 2017-12-08 | 2020-03-24 | Astrazeneca Ab | Chemical compounds |
| EP3964516A4 (en) * | 2019-04-28 | 2023-01-11 | Genfleet Therapeutics (Shanghai) Inc. | OXAAZACHUINAZOLINE-7( 8H)-KETONE COMPOUND, PROCESS FOR ITS PRODUCTION AND ITS PHARMACEUTICAL APPLICATION |
| CN113396147B (zh) * | 2019-05-31 | 2024-06-18 | 上海翰森生物医药科技有限公司 | 芳香杂环类衍生物调节剂、其制备方法和应用 |
| WO2020259573A1 (zh) * | 2019-06-25 | 2020-12-30 | 南京明德新药研发有限公司 | 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物 |
| WO2021000885A1 (zh) * | 2019-07-01 | 2021-01-07 | 江苏恒瑞医药股份有限公司 | 喹唑啉酮类衍生物、其制备方法及其在医药上的应用 |
| CN114195804A (zh) * | 2019-07-30 | 2022-03-18 | 上海凌达生物医药有限公司 | 一类哌啶稠环类化合物、制备方法和用途 |
| CN112300194B (zh) * | 2019-07-30 | 2022-01-14 | 上海凌达生物医药有限公司 | 一类稠环吡啶酮类化合物、制备方法和用途 |
| IL290276B2 (en) * | 2019-08-02 | 2026-05-01 | Shanghai Jemincare Pharmaceuticals Co Ltd | Tetracyclic compounds, method for their preparation and use |
| CN112390818B (zh) * | 2019-08-12 | 2023-08-22 | 劲方医药科技(上海)有限公司 | 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途 |
| CN114615981B (zh) * | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| CN116947885B (zh) * | 2019-09-20 | 2026-01-23 | 上海济煜医药科技股份有限公司 | 稠合吡啶酮类化合物及其制备方法和应用 |
| BR112022008375A2 (pt) * | 2019-10-30 | 2022-07-12 | Genfleet Therapeutics Shanghai Inc | Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste |
| CN113321654B (zh) * | 2020-02-28 | 2022-05-03 | 上海济煜医药科技有限公司 | 作为激酶抑制剂的稠合吡啶酮类化合物 |
| AU2021248363B2 (en) * | 2020-04-03 | 2024-02-15 | Medshine Discovery Inc. | Octahydropyrazinodiazanaphthyridine dione compounds |
| TW202144349A (zh) * | 2020-04-30 | 2021-12-01 | 大陸商上海科州藥物研發有限公司 | 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法 |
| CN113929681A (zh) * | 2020-07-14 | 2022-01-14 | 浙江海正药业股份有限公司 | 四环类衍生物及其制备方法和用途 |
| CN113980032B (zh) * | 2020-07-27 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
| CN114195788B (zh) * | 2020-09-17 | 2024-10-01 | 苏州闻天医药科技有限公司 | 一类四环化合物及其用途 |
| CN116670136A (zh) * | 2020-12-31 | 2023-08-29 | 正大天晴药业集团股份有限公司 | 四环类化合物及其医药用途 |
| CN115557974A (zh) * | 2021-07-02 | 2023-01-03 | 上海迪诺医药科技有限公司 | Kras g12d抑制剂及其应用 |
-
2022
- 2022-07-19 CA CA3226720A patent/CA3226720A1/en active Pending
- 2022-07-19 WO PCT/CN2022/106447 patent/WO2023001141A1/en not_active Ceased
- 2022-07-19 JP JP2024527720A patent/JP2024525993A/ja active Pending
- 2022-07-19 KR KR1020247005823A patent/KR20240087636A/ko active Pending
- 2022-07-19 EP EP22845306.4A patent/EP4373827A4/en active Pending
- 2022-07-19 US US18/290,798 patent/US20240376123A1/en active Pending
- 2022-07-19 AU AU2022314009A patent/AU2022314009A1/en active Pending
- 2022-07-19 CN CN202280009851.5A patent/CN117242079A/zh active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020519589A (ja) * | 2017-05-11 | 2020-07-02 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | Ｇ１２ｃ変異型ｒａｓタンパク質を阻害するヘテロアリール化合物 |
| WO2019215203A1 (en) * | 2018-05-08 | 2019-11-14 | Astrazeneca Ab | Tetracyclic heteroaryl compounds |
| JP2024500105A (ja) * | 2020-12-15 | 2024-01-04 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | ポリヌクレオチドの改善されたインビトロアセンブリーのための組成物及び方法 |
| JP2024510022A (ja) * | 2021-03-17 | 2024-03-05 | ▲勁▼方医▲薬▼科技（上海）有限公司 | ピリミジン縮合環系化合物、その製造方法、及び使用 |
| JP2024513866A (ja) * | 2021-04-04 | 2024-03-27 | 華為技術有限公司 | データ伝送方法及び装置 |
| JP2024522766A (ja) * | 2021-06-21 | 2024-06-21 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合四環系化合物、その調製方法及びその医薬的応用 |
| JP2024545001A (ja) * | 2021-11-16 | 2024-12-05 | ワッカー ケミー アクチエンゲゼルシャフト | 亜ハロゲン化ケイ素含有複合粒子 |
| JP2025513258A (ja) * | 2022-04-21 | 2025-04-24 | ギリアード サイエンシーズ， インコーポレイテッド | Ｋｒａ ｇ１２ｄ調節化合物 |
Non-Patent Citations (1)
| Title |
|---|
| REGISTRY（STN）[ONLINE], JPN7026001293, 10 October 2019 (2019-10-10), ISSN: 0005826480 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024510022A (ja) * | 2021-03-17 | 2024-03-05 | ▲勁▼方医▲薬▼科技（上海）有限公司 | ピリミジン縮合環系化合物、その製造方法、及び使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023001141A1 (en) | 2023-01-26 |
| KR20240087636A (ko) | 2024-06-19 |
| AU2022314009A1 (en) | 2024-01-25 |
| CN117242079A (zh) | 2023-12-15 |
| EP4373827A1 (en) | 2024-05-29 |
| US20240376123A1 (en) | 2024-11-14 |
| EP4373827A4 (en) | 2025-06-04 |
| CA3226720A1 (en) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20240087636A (ko) | Kras g12d 억제제 및 이의 용도 | |
| CN116143805B (zh) | 一类含氮杂环联芳基类化合物、制备方法和用途 | |
| WO2023284537A1 (en) | Kras g12d inhibitors and uses thereof | |
| CN120882724A (zh) | Kras g12d抑制剂和其用途 | |
| WO2023030517A1 (en) | Kras g12c inhibitors and uses thereof | |
| WO2024153119A1 (en) | Kras g12d inhibitors and uses thereof | |
| CN117222646A (zh) | Kras g12c抑制剂和其用途 | |
| AU2021283585A1 (en) | Inhibitors of KRAS G12C protein and uses thereof | |
| JP2024537372A (ja) | 新規なピリミドピリジン化合物、その医薬組成物及びその使用 | |
| JP7465945B2 (ja) | Ｂｅｔ阻害剤としてのヘテロ環式化合物 | |
| AU2024333376A1 (en) | Kras inhibitors and uses thereof | |
| WO2025153038A1 (en) | Kras inhibitors and uses thereof | |
| CN117800976A (zh) | 一类含氮杂环类化合物、制备方法和用途 | |
| JP2022501338A (ja) | 抗腫瘍剤としてのキナゾリン誘導体 | |
| JP2024522766A (ja) | 縮合四環系化合物、その調製方法及びその医薬的応用 | |
| WO2025157246A1 (zh) | 嘧啶多环类衍生物抑制剂、其制备方法和应用 | |
| WO2022247816A1 (zh) | 含氮杂环类化合物、其制备方法及其在医药上的应用 | |
| JP2023537055A (ja) | Ａｔｒ阻害剤およびその使用 | |
| WO2015049629A1 (en) | Imidazoquinoline compounds as bromodomain inhibitors | |
| CN115636833A (zh) | 作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途 | |
| TW202216701A (zh) | Atr抑制劑及其用途 | |
| WO2023051464A1 (en) | Pyrazolopyridine compounds as tam inhibitors | |
| TW202218661A (zh) | 作為ｅｇｆｒ抑制劑的三環化合物 | |
| TW202320767A (zh) | 雜芳基衍生物parp抑制劑及其用途 | |
| WO2023138621A1 (en) | Atr inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250718 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250718 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260327 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260326 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260629 |